ReviewJournal of advanced research2023
Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment.
Review in Journal of advanced research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Proton pump inhibitors and risk of Parkinson's disease: A systematic review and meta-analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Neurotransmitter-mediated gut-brain axis: a bibliometric analysis of research trends and knowledge structure.Frontiers in microbiology · 2026Pooled it
- The role of the gut microbiome in the progression of Parkinson's disease: a systematic review of patient cohorts.Journal of neurology · 2025Pooled it
- Safety and efficacy of fecal microbiota transplantation in the treatment of Parkinson's disease: a systematic review of clinical trials.Frontiers in neuroscience · 2025Pooled it
- Hesperetin mitigates IBD-associated bone loss viaJournal of orthopaedic translation · 2026Article
- Metabolic shifts driven by host-microbial interactions.The FEBS journal · 2026Review
- Gut-brain axis dysregulation in Parkinson's disease: Mechanisms linking microbiota to neuroinflammation and α-synuclein pathology.Journal of pharmaceutical analysis · 2026Review
- Integrative Analysis Reveals Interactions Between Gut Microbiota-Derived Metabolites and the Brain in Parkinson's Disease.Molecular neurobiology · 2026Article
- Neuroinflammation in Alzheimer's and Parkinson's diseases: pathogenic mechanisms and therapeutic strategies.Translational neurodegeneration · 2026Review
- Research Progress on the Anti-Inflammatory and Antioxidant Effects of Daidzein: Its Mechanisms of Action in Related Diseases, and Related Nanoformulations to Enhance Its Bioavailability.Antioxidants (Basel, Switzerland) · 2026Review
- Disease modification in advanced Parkinson's disease: a review and roadmap for paving the way for next-generation interventions.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Regulation Progresses of Selenium Improving Intestinal and Extra-Intestinal Tissues Health Through Regulating Gut Microbiota.Biology · 2026Review
- Branched-chain amino acids ameliorate CD4NPJ Parkinson's disease · 2026Article
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Bridging the Gut Microbiota and the Brain, Kidney, and Cardiovascular Health: The Role of Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease.Neurotoxicity research · 2026Article
- The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions.Microorganisms · 2026Review
- Potential common pathogenesis of several neurodegenerative diseases.Neural regeneration research · 2026Article
- Microenvironment Self-Adaptive Nanoarmor to Address Adhesion- and Colonization-Related Obstacles in Impaired Intestine Promote Bacteriotherapy Against Parkinson's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Gut microbiota and Parkinson's disease: exploring pathogenesis and potential therapeutic strategies from a gut-brain axis perspective.iScience · 2026Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a disease of ⍺-synuclein aggregation-mediated dopaminergic neuronal loss in the substantia nigra pars compacta, which leads to motor and non-motor symptoms. Through the last two decades of research, there has been growing consensus that inflammation-mediated oxidative stress, mitochondrial dysfunction, and cytokine-induced toxicity are mainly involved in neuronal damage and loss associated with PD. However, it remains unclear how these mechanisms relate to sporadic PD, a more common form of PD. Both enteric and central nervous systems have been implicated in the pathogenesis of sporadic PD, thus highlighting the crosstalk between the gut and brain.
aimof Review: In this review, we summarize how alterations in the gut microbiome can affect PD pathogenesis. We highlight various mechanisms increasing/decreasing the risk of PD development. Based on the previous supporting evidence, we suggest how early interventions could protect against PD development and how controlling specific factors, including our diet, could modify our perspective on disease mechanisms and therapeutics. We explain the strong relationship between the gut microbiota and the brain in PD subjects, by delineating the multiple mechanisms involved inneuroinflammation and oxidative stress. We conclude that the neurodetrimental effects of western diet (WD) and the neuroprotective effects of Mediterranean diets should be further exploredin humans through clinical trials. Key Scientific Concepts of Review: Alterations in the gut microbiome and associated metabolites may contribute to pathogenesis in PD. In some studies, probiotics have been shown to exert anti-oxidative effects in PD via improved mitochondrial dynamics and homeostasis, thus reducing PD-related consequences. However, there is a significant unmet need for randomized clinical trials to investigate the effectiveness of microbial products, probiotic-based supplementation, and dietary intervention in reversing gut microbial dysbiosis in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.